Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Approval: CareFlight Limited

I, Christopher Paul Burgess, Chief Health Officer:

(a) under section 254(1) of the *Medicines, Poisons and Therapeutic Goods Act 2012 (**the Act**)*, approve each Scheduled substance treatment protocol specified in Schedule A, and

(b) under section 254(3) of the Act, state that each Schedule Substance Treatment Protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this Notice.

Dated 29 October 2026

Chief Health Officer

Schedule A

Title	Publication Date	Author
CareFlight Limited - SSTP	29 October 2026	Medicines and Poisons Northern Territory Government, NT Health

CareFlight Limited - SSTP

Areas Applicable	NT Wide
Health Professionals authorised by this SSTP	Nurses, Midwives and Paramedics employed by or contracted to CareFlight Limited ABN 18 210 132 023

Scheduled Substance(s)

Schedule 3 and 4 medicines			
Acetylcysteine	Furosemide	Metoprolol	Propofol
Aciclovir	Gentamicin	Metronidazole	Rocuronium
Adenosine	Glyceryl Trinitrate	Midazolam	Ropivicaine
Adrenaline - epinephrine	Gramicidin	Misoprostol	Salbutamol
Alprostadil	Haloperidol	Mupirocin	Sulfamethoxazole
Amiodarone	Homatropine	Naloxone	Suxamethonium
Antisera	Hydralazine	Naproxen	Tenecteplase
Atropine	Hydrocortisone	Neomycin	Terlipressin
Benzatropine	Hyoscine	Nifedipine	Tetracaine
Benzyl Penicillin	Hyoscine Butylbromide	Noradrenaline	Thiopentone
Betamethasone	Ibuprofen	Nystatin	Tramadol
Ceftriaxone	Insulin	Olanzapine	Tranexamic Acid
Chlorpromazine	Ipratropium	Omeprazole	Triamcinolone acetonide
Clopidogrel	Isosorbide dinitrate	Ondansetron	Trimethoprim
Dexamethasone	Labetalol	Oxytocin	Vancomycin
Diazepam	Levetiracetam	Pancuronium	
Diclofenac	Lidocaine	Paracetamol	**Schedule 8 Medicines**
Dobutamine	Loperamide	Phenobarbitone	Alfentanil
Dopamine	Magnesium Sulfate	Phenytoin	Codeine
Doxylamine	Mefenamic Acid	Poractant	Fentanyl
Droperidol	Meropenem	Potassium Chloride	Ketamine
Enoxaparin	Metaraminol	Prochlorperazine	Morphine
Ergometrine	Metoclopramide	Promethazine	Oxycodone

<table>
<tr><td>Indication, Dose, Route, Frequency</td><td colspan="3">Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in CareFlight Medication Guidelines as in force from time to time.
Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner.</td></tr>
<tr><td>Contraindications and/or Exclusions*</td><td colspan="3">Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol.
Any contraindications or exclusions as outlined in the individual scheduled substance product information.
Any contraindication or exclusions as outlined in CareFlight Medication Guidelines as in force from time to time.</td></tr>
<tr><td>Health Professional Accreditation Requirements</td><td colspan="3"><u>Nurses and Midwives must:</u>
Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients
Maintain continuing professional development related to skills and competencies required for delivery of medicines
<u>Paramedics must:</u>
Hold registration with the Paramedicine Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients
Maintain continuing professional development related to skills and competencies required for delivery of medicines</td></tr>
<tr><td rowspan="2">Chief Health Officer</td><td>Signature</td><td>Name</td><td>Date</td></tr>
<tr><td>EDOC 09-D26-92443</td><td>Paul Burgess</td><td>29/10/2026</td></tr>
<tr><td>Period of effect</td><td colspan="3">This SSTP is in effect until 29/10/2028 unless revoked earlier</td></tr>
<tr><td colspan="4">References:
* The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration</td></tr>
</table>